Pirtobrutinib Produces Durable Responses in Relapsed/Refractory MCL
Pirtobrutinib has shown clinical activity in a phase 1/2 trial of patients with relapsed or refractory mantle cell lymphoma.
All articles by Julie Ehlers
About 20% of Oncologists Studied Left Patient-Facing Positions Between 2015 and 2022
In a study of 16,870 oncologists practicing in the United States, 21% left patient-facing roles between 2015 and 2022.
New Documentation Tool Improves Telephone Triage in Oncology Pain Management
A new pain assessment documentation tool is helping nurses in an ambulatory clinic better manage telephone triage in oncology care.
New Scale Quantifies Workload, Increases Productivity of Oncology Nurse Navigators
Study results show a new productivity scale measures the workloads of oncology nurse navigators and assists in increasing their productivity.
Heart Failure Rates After Carfilzomib Similar in Black and White MM Patients
New research suggests that carfilzomib increases the risk of heart failure in patients with multiple myeloma, but the risk does not appear to vary between Black and White patients.
Belantamab Mafodotin Deemed Safe, Effective in Real-World MM Population
Belantamab mafodotin has shown clinical activity and a manageable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma.
Pediatric Cancer Survivors Have 4-Fold Higher Risk of Death 40 Years After Diagnosis
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...